Pharmaceutical company working in the field of pathogen-host signal transduction selects software platform for managing chemical and biological drug discovery data
IDBS, provider of integrated data management, analysis and decision-making software for biopharmaceutical discovery research, says that Axxima Pharmaceuticals has implemented IDBS's ActivityBase as its corporate software platform for managing chemical and biological drug discovery data.
Axxima, a drug discovery and development company in the field of pathogen-host signal transduction, is developing small molecule drugs to combat infections and related diseases, such as inflammation, by blocking critical signal transduction pathways required by pathogens for their survival.
Axxima selected ActivityBase to unite chemical structures and physico-chemical properties, with results from biological tests, providing a common informatics environment for chemists and biologists across its organisation to share, discuss and interpret data. "ActivityBase corroborates the close proximity of our in-house chemistry and biology in a very efficient way, thus speeding up our drug discovery process.
"We have deployed ActivityBase across the organisation and it is meeting the needs of managers, bench scientists and database experts alike," said Gerhard Muller, chief scientific officer at Axxima.
Andrea Missio, director of chemistry at Axxima, said: "With ActivityBase we have a software platform which is more than just a repository of data.
"It is an advanced application which encourages scientists to share data, carry out sophisticated queries on that data, and to ultimately develop unique knowledge in kinase research".
Axxima is one of several reference sites for ActivityBase, enabling other biotechnology companies to get first hand feedback on the software from their peers in the industry.
In addition to screening data, ActivityBase is supporting lead optimisation projects at Axxima by capturing key data such as selectivity or solubility.
"One aspect of the system that we find extremely useful is the ability to decompose molecules from a central core to see which R-groups affect activity," said Missio.
Neil Kipling, chairman and CEO of IDBS commented: "It is an honour for us that Axxima, at the cutting edge of kinase research, has volunteered to be a reference site for ActivityBase.
"ActivityBase supports discovery research operations in most of the large pharmaceutical organisations.
"Leading biotech companies such as Axxima are increasingly recognising the business benefits of a standard platform, based on more than ten years of experience, to integrate biology and chemistry."
